Most Read Articles
Dr. Joseph Delano Fule Robles, 14 Nov 2017

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
Both hatha yoga and a low-FODMAP (Fermentable, Oligo-, Di-, Monosaccharides and Polyol) diet can alleviate gastrointestinal symptoms, as well as improve a range of other psychological and physiological health parameters, in patients with irritable bowel syndrome (IBS), a study has shown.
6 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

Product Highlight - Keytruda

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
  • Efficient: Significant efficacy and durable response. 41% ORR whose tumors expressed ≥50% PD-L1 and 84% of patients OR had ongoing responses1,2
  • Predictive: In NSCLC, testing for PD-L1 expression helps to identify patients most likely to respond and to develop a patient’s treatment algorithm1
  • Practical: Convenience dosing of 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks3
  • Manageable Safety Profile: Most of the common adverse reactions were grade 1 or 24
  • PD-1 Blockade: Selectively targets PD-1 directly on the T-cell for the complete PD-1 pathway blockade of both PD-L1 and PD-L2 ligands4

References:
1. Supplement to: Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
2. Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
3. Keytruda pack insert LPC-MK 3475-IV-122015
4. Herbst RS et.al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016; 387 (10027): 1540-1550


Further and safety information is available in section 9d, New In This Issue and mims.com.
Full prescribing information is available upon request.
ONCO-1199329-0000 10/16

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 14 Nov 2017

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
Both hatha yoga and a low-FODMAP (Fermentable, Oligo-, Di-, Monosaccharides and Polyol) diet can alleviate gastrointestinal symptoms, as well as improve a range of other psychological and physiological health parameters, in patients with irritable bowel syndrome (IBS), a study has shown.
6 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.